151 related articles for article (PubMed ID: 33082556)
1. Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia.
Barrow TM; Nakjang S; Lafta F; Bilotkach K; Woodhouse L; Junge G; Tudhope SJ; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Strathdee G
Br J Cancer; 2021 Jan; 124(2):474-483. PubMed ID: 33082556
[TBL] [Abstract][Full Text] [Related]
2. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
[TBL] [Abstract][Full Text] [Related]
3. ZNF718, HOXA4, and ZFP57 are differentially methylated in periodontitis in comparison with periodontal health: Epigenome-wide DNA methylation pilot study.
Hernández HG; Hernández-Castañeda AA; Pieschacón MP; Arboleda H
J Periodontal Res; 2021 Aug; 56(4):710-725. PubMed ID: 33660869
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
6. Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia.
Humphries LA; Godbersen JC; Danilova OV; Kaur P; Christensen BC; Danilov AV
Br J Haematol; 2013 Dec; 163(5):590-602. PubMed ID: 24117128
[TBL] [Abstract][Full Text] [Related]
7. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
Wolf C; Garding A; Filarsky K; Bahlo J; Robrecht S; Becker N; Zucknick M; Rouhi A; Weigel A; Claus R; Weichenhan D; Eichhorst B; Fischer K; Hallek M; Kuchenbauer F; Plass C; Döhner H; Stilgenbauer S; Lichter P; Mertens D
Int J Cancer; 2018 Jan; 142(2):322-333. PubMed ID: 28921505
[TBL] [Abstract][Full Text] [Related]
8. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
[TBL] [Abstract][Full Text] [Related]
9. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.
Raval A; Lucas DM; Matkovic JJ; Bennett KL; Liyanarachchi S; Young DC; Rassenti L; Kipps TJ; Grever MR; Byrd JC; Plass C
J Clin Oncol; 2005 Jun; 23(17):3877-85. PubMed ID: 15809452
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide DNA methylation profiling integrated with gene expression profiling identifies
Rani L; Mathur N; Gupta R; Gogia A; Kaur G; Dhanjal JK; Sundar D; Kumar L; Sharma A
Clin Epigenetics; 2017; 9():57. PubMed ID: 28572861
[TBL] [Abstract][Full Text] [Related]
11. Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia.
Irving L; Mainou-Fowler T; Parker A; Ibbotson RE; Oscier DG; Strathdee G
Epigenetics; 2011 Mar; 6(3):300-6. PubMed ID: 21051931
[TBL] [Abstract][Full Text] [Related]
12. Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia.
Papakonstantinou N; Ntoufa S; Tsagiopoulou M; Moysiadis T; Bhoi S; Malousi A; Psomopoulos F; Mansouri L; Laidou S; Papazoglou D; Gounari M; Pasentsis K; Plevova K; Kuci-Emruli V; Duran-Ferrer M; Davis Z; Ek S; Rossi D; Gaidano G; Ritgen M; Oscier D; Stavroyianni N; Pospisilova S; Davi F; Ghia P; Hadzidimitriou A; Belessi C; Martin-Subero JI; Pott C; Rosenquist R; Stamatopoulos K
Int J Cancer; 2019 Jun; 144(11):2695-2706. PubMed ID: 30447004
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylation coordinates antagonistically with hypermethylation in cancer development: a case study of leukemia.
Kushwaha G; Dozmorov M; Wren JD; Qiu J; Shi H; Xu D
Hum Genomics; 2016 Jul; 10 Suppl 2(Suppl 2):18. PubMed ID: 27461342
[TBL] [Abstract][Full Text] [Related]
14. Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL.
Subhash S; Andersson PO; Kosalai ST; Kanduri C; Kanduri M
Clin Epigenetics; 2016; 8():106. PubMed ID: 27777635
[TBL] [Abstract][Full Text] [Related]
15. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
[TBL] [Abstract][Full Text] [Related]
16. Altered DNA Methylation Profiles in
Pacholewska A; Grimm C; Herling CD; Lienhard M; Königs A; Timmermann B; Altmüller J; Mücke O; Reinhardt HC; Plass C; Herwig R; Hallek M; Schweiger MR
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502260
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
Ljungström V; Cortese D; Young E; Pandzic T; Mansouri L; Plevova K; Ntoufa S; Baliakas P; Clifford R; Sutton LA; Blakemore SJ; Stavroyianni N; Agathangelidis A; Rossi D; Höglund M; Kotaskova J; Juliusson G; Belessi C; Chiorazzi N; Panagiotidis P; Langerak AW; Smedby KE; Oscier D; Gaidano G; Schuh A; Davi F; Pott C; Strefford JC; Trentin L; Pospisilova S; Ghia P; Stamatopoulos K; Sjöblom T; Rosenquist R
Blood; 2016 Feb; 127(8):1007-16. PubMed ID: 26675346
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic and genetic alterations and their influence on gene regulation in chronic lymphocytic leukemia.
Huang D; Ovcharenko I
BMC Genomics; 2017 Mar; 18(1):236. PubMed ID: 28302063
[TBL] [Abstract][Full Text] [Related]
19. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL.
Strathdee G; Sim A; Parker A; Oscier D; Brown R
Leukemia; 2006 Jul; 20(7):1326-9. PubMed ID: 16688227
[No Abstract] [Full Text] [Related]
[Next] [New Search]
